Alain P. Algazi
University of California, San Francisco(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Head and Neck Cancer Studies, Melanoma and MAPK Pathways
Most-Cited Works
- → Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma(2013)3,383 cited
- → Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,654 cited
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma(2016)1,053 cited
- → Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12(2018)911 cited
- → Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial(2012)901 cited
- → Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC(2017)553 cited
- → The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies(2015)552 cited
- → Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma(2016)516 cited